688321 Shenzhen Chipscreen Biosciences
- 21.24
- -0.34-1.58%
Shenzhen Chipscreen Biosciences News
Microchip Biotech (688321.SH): The company currently has capital reserves of about 1 billion yuan
Gelonghui, May 17丨Microchip Biotech (688321.SH) recently said during a survey from institutional investors that the company currently has about 1 billion yuan in capital reserves, including cash on hand, bank financial management, and issued but not yet fully used bond funds. The R&D investment in the next two years is expected to be about the same as last year. Since clinical trials are carried out in stages, capital investment is also gradually increasing, so it is possible to avoid spending a large amount of money at once. The company focuses on improving the efficiency of capital use and controlling costs by optimizing clinical trial design and operation. The company adopts strategies to reduce costs and increase efficiency to ensure continuous research
Microchip Biotech (688321.SH): Prices of sidabendamide and siglitazide are expected to remain relatively stable over the next two years
Gelonghui, May 17丨Microchip Biotech (688321.SH) recently said during a survey receiving institutional investors that the PTCL indications for sidabonamide have now been included in national health insurance for the fourth time, and the DLBCL indications were approved at the end of April. They are in line with the conditions for participating in national health insurance negotiations in the second half of this year, and additional indications are included in medical insurance. How to maintain access to medicines and the profitability of the company through health insurance negotiations is an ongoing task of the company. The company expects the prices of sidabendamide and siglitazide to remain relatively stable over the next two years.
Shenzhen Chipscreen Biosciences (SHSE:688321) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) announced strong profits, but the stock was stagnant. Our analysis suggests that this might be because shareholders have noticed some concernin
Microchip Biotech (688321.SH): Net loss of 18.30.46 million yuan in the first quarter
Gelonghui, April 28, 丨 Microchip Biotech (688321.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 131 million yuan, an increase of 22.60% over the previous year; net profit attributable to shareholders of listed companies - 183,046 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 219.761 million yuan; and basic earnings per share - 0.0448 yuan.
Revenues Tell The Story For Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) As Its Stock Soars 26%
Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. Unfor
Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders
Shenzhen Chipscreen Biosciences (SHA:688321) said holders of its microchip convertible bonds will have the option to sell back their bonds to the company at 100.49 yuan per unit, according to a filing
Individual Investors Invested in Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) Copped the Brunt of Last Week's CN¥461m Market Cap Decline
Key Insights Significant control over Shenzhen Chipscreen Biosciences by individual investors implies that the general public has more power to influence management and governance-related decisions
Microchip Biotech (688321.SH): Application for clinical trial of Theoroni capsules to treat pancreatic cancer accepted
Gelonghui, April 9 | Microchip Biotech (688321.SH) announced that the company and its wholly-owned subsidiary Chengdu Microchip Pharmaceutical Co., Ltd. recently received an “Notice of Acceptance” issued by the State Drug Administration for the registration of clinical trials of domestically produced drugs, and the clinical trial application for the treatment of pancreatic cancer with Theoroni capsules was accepted.
Microchip Biotech (688321.SH): A total cost of 14.995,500 yuan to buy back 0.18% of shares
Gelonghui, April 8, 丨 Microchip Biotech (688321.SH) announced that as of April 3, 2024, the company had repurchased a total of 7483.88 million shares of the company's shares through centralized bidding transactions, accounting for 0.18% of the company's total share capital of 411,286,794 shares. The highest price of the repurchase transaction was 20.98 yuan/share, the lowest price was 16.24 yuan/share, and the total amount of capital paid was RMB 14,995,513.61 (excluding transaction fees such as stamp duty and transaction fees). Currently, all of them are stored in Special securities for repurchase of company shares
Microchip Biology (688321.SH): Phase III data on small cell lung cancer is expected to be revealed from April to May
Gelonghui, April 8 | Microchip Biotech (688321.SH) said on the investor interactive platform that according to the progress of the clinical project, the company expects stage III data for small cell lung cancer to be revealed from April to May. The specific data reading time will be determined based on progress after the findings are revealed.
Microchip Biotech (688321.SH): A total of 136,800 shares have been repurchased
Gelonghui, April 2, 丨 Microchip Biotech (688321.SH) announced that as of March 31, 2024, the company had repurchased a total of 136,794 shares through the Shanghai Stock Exchange trading system, accounting for 0.03% of the company's total share capital of 411,286,794 shares. The highest price of the repurchase transaction was 16.61 yuan/share, the lowest price was 16.24 yuan/share, and the total amount of capital paid was RMB 2,253,489 (excluding transaction fees such as stamp duty and transaction fees).
Microchip Biotech (688321.SH): Net profit of 888.385 million yuan in 2023 increased 408.09% year-on-year
Gelonghui, March 29丨Microchip Biotech (688321.SH) released its 2023 annual report. Operating revenue for the reporting period was 524 million yuan, down 1.18% year on year; net profit attributable to shareholders of listed companies was 888.385 million yuan, up 408.09% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 217 million yuan; basic income per share was 0.2176 yuan.
Microchip Biotech (688321.SH): initial repurchase of 86,800 shares
Gelonghui, March 26, 丨 Microchip Biotech (688321.SH) announced that on March 26, 2024, the company repurchased 86,794 shares for the first time through the Shanghai Stock Exchange trading system, accounting for 0.02% of the company's total share capital of 411,286,794 shares. The highest price of the repurchase transaction was 16.61 yuan/share, the lowest price was 16.44 yuan/share, and the total amount of capital paid was RMB 1,433,181 (excluding transaction fees such as stamp duty and transaction fees).
Microchip Biotech (688321.SH): The company will use AI technology to accelerate R&D
Gelonghui March 22丨Microchip Biotech (688321.SH) said on the investor interactive platform that the company will use AI technology to speed up R&D. The company introduced AI technology platforms such as the HUAWEI CLOUD medical intelligence EiHealth platform based on the Pangu drug model and the Hermite drug calculation design platform of Shenshi Technology into an integrated drug discovery and early evaluation platform based on chemical genomics, using artificial intelligence, physical modeling, and high-performance computing to help the company's early R&D projects. Let the company's core technology platform better discover pioneers, improve R&D efficiency, and reduce R&D
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 30% Share Price Surge Not Quite Adding Up
Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) shareholders are no doubt pleased to see that the share price has bounced 30% in the last month, although it is still struggling to make up rece
Microchip Biotech (688321.SH): No share repurchase has been implemented
Gelonghui March 1 丨 Microchip Biotech (688321.SH) announced that as of February 29, 2024, the company had not implemented a share repurchase.
Microchip Biotech (688321.SH) performance report: 2023 net profit of 888.418 million yuan increased 408.11% year-on-year
Gelonghui, Feb. 23: Microchip Biotech (688321.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 526.584 million yuan, a year-on-year decrease of 1.19%; realized net profit attributable to owners of the parent company of 888.418 million yuan, an increase of 408.11% over the previous year; realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses of 217.4956 million yuan, a year-on-year decrease of 3,433.88%.
Shenzhen Chipscreen Biosciences (SHSE:688321) Is Making Moderate Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might
Microchip Biotech (688321.SH): Plans to spend 8 million yuan to 15 million yuan to buy back the company's shares
Gelonghui, Feb. 6 | Microchip Biotech (688321.SH) announced that the company plans to use its own or self-raised funds to repurchase some of the company's issued A shares through centralized bidding transactions, with a total repurchase capital of not less than RMB 8 million (inclusive) and no more than RMB 15 million (inclusive); under the condition that the repurchase price does not exceed RMB 28.47 per share, according to the maximum repurchase amount of RMB 15 million, the number of repurchases is approximately RMB 526,900 shares, accounting for about 0.13% of the company's total share capital; according to the minimum repurchase limit of RMB 8 million According to estimates, the number of repurchases is about 2
Microchip Biotech (688321.SH): Chairman and general manager proposed 8 million yuan to 15 million yuan to repurchase shares
Gelonghui, January 31 | Microchip Biotech (688321.SH) announced that Dr. Xian PING LU (Lu Xianping), the company's actual controller, chairman and general manager, proposed to use the company's own funds or self-raised funds to repurchase some of the company's issued RMB common shares (A shares) through centralized bidding transactions. The total repurchase capital should not be less than RMB 8 million (inclusive), not more than RMB 15 million (inclusive).
Analysis
Price Target
No Data
